Eyecelerator, Unither Pharmaceuticals and Ora have announced the launch of ‘Eye to Market’, a new web series dedicated to accelerating understanding of how ophthalmic innovations move from scientific insight to real-world adoption.  

The series will bring together leaders across research, clinical development, manufacturing, and commercialisation to unpack the challenges and opportunities shaping the future of eye care.  

It aims to highlight the steps required to bring breakthrough ophthalmic solutions to patients worldwide — from early-stage development through clinical validation, scale-up, regulatory strategy, and market access. 

“Eye to Market was created to demystify the innovation pathway in ophthalmology,” said Gil Kliman, Program Director for Eyecelerator. “By opening the conversation across disciplines, we hope to help innovators and partners navigate complexity and ultimately deliver better outcomes for patients.” 

Unither Pharmaceuticals will contribute its expertise in sterile manufacturing and drug delivery systems supporting ophthalmic innovation and accessibility. Ora brings clinical development insight and a proven track record of advancing therapeutic and device innovation. 

“Partnership and cross-functional collaboration are essential to transform promising ideas into approved, scalable treatments,” said Brian Kenyon, Business Development, North America, for UnitherPharmaceuticals. 

“From first-in-human studies through global commercialisation, successful product development requires more than technical execution—it demands insight, experience, and empathy,” added Ora Chief Scientific Officers George Ousler and Keith Lane. “This series highlights the power of rigorous science, collaboration, and a shared commitment to patients—bringing together industry‑leading experts to illuminate the pathway from innovation to impact in ophthalmology.”